Table 1

Baseline characteristics of patients with inoperable chronic thromboembolic pulmonary hypertension, based on participation in cardiac rehabilitation

Non-CR groupCR groupp Value
Patients (n)2417
Age (years, range)66±10 (49–85)70±7 (53–82)0.16
Sex (female/male)20/410/70.08#
Body mass index (kg/m2)22.4±3.822.2±3.30.85
WHO-FC (I/II/III/IV)1/21/2/00/14/3/00.26##
Patients previously treated with PEA (n, %)3 (13)1 (6)0.48#
Disease duration before the first BPA (months)66 (29–127)53 (20–86)0.23##
Pulmonary hypertension-specific therapy (n, %)15 (63)10 (59)0.81#
6-min walk distance (m)468±102498±960.34
Brain natriuretic peptide level (pg/mL)28 (16–39)22 (15–41)0.56##
Haemodynamic data
 Mean PAP (mm Hg)24.9±4.924.5±6.40.80
 Mean RAP (mm Hg)1.5 (0.0–3.0)1.0 (0.5–2.0)0.17##
 Cardiac index (L/min/m2)2.54±0.532.62±0.500.63
TPR (dyne.s/cm5)544±189507±1780.53
CPX parametersn=22n=17
 Peak work load (W)81±1985±230.53
 Peak VO2 (mL/min/kg)17.8±2.617.4±2.60.61
 Peak VO2% predicted (%)69.7±12.370.7±9.40.78
 VE-VCO2 slope37.6±6.842.1±10.20.11
  • Results are expressed as mean±SD or median (25% and 75% centile) unless otherwise indicated.

  • p Values from #χ2 tests, ##the Mann–Whitney U test, or otherwise t tests.

  • BPA, balloon pulmonary angioplasty; CPX, cardiopulmonary exercise testing; CR, cardiac rehabilitation; PAP, pulmonary arterial pressure; PEA, pulmonary endarterectomy; RAP, right atrial pressure; TPR, total pulmonary resistance; VCO2, carbon dioxide production; VO2, oxygen uptake; VE, minute ventilation; WHO-FC, WHO functional class.